Because it is considered more receptor-selective than several earlier GH peptides, educational discussions often highlight ipamorelin for targeted GH-axis stimulation with comparatively minimal downstream influence on markers commonly associated with broader pituitary activation (such as cortisol, prolactin, and ACTH ) in experimental settings
Plan around the 28-30 day stability window for both compounds
Ipamorelin Research Summary Ipamorelin is a synthetic pentapeptide GHS-R1a agonist designed at Novo Nordisk in the mid-1990s as a receptor-selective successor to the GHRP-1, GHRP-2, GHRP-6, Hexarelin lineage developed through the GHRP discovery work of Cyril Y
Survodutide is a dual GLP-1/glucagon receptor agonist, not a triple agonist
Your Klinic provider in Louisville will help choose which solution best suits your unique medical and insurance circumstances
And on that note, see these photos of a man on brentuximab, and his hair before and after treatment (Penzi et al., 2017)